Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma

Zhang, Jing; Jiang, Wei; Wang, Wei-Da; Liu, Cheng-Cheng; Hu, Yan-Ping; Xia, Zhong-Jun

추천

검색

자료유형: 학술저널

저자정보: Zhang, Jing (Department of Medical Oncology, Hubei Cancer Hospital) Jiang, Wei (Department of Radiation Oncology, the Affiliated Hospital of Guilin Medical University) Wang, Wei-Da (Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center) Liu, Cheng-Cheng (Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center) Hu, Yan-Ping (Department of Medical Oncology, Hubei Cancer Hospital) Xia, Zhong-Jun (Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제11호

발행연도: 2015.1

수록면: 4,515 - 4,520 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

GELOX (gemcitabine, oxaliplatin and L-asparaginase) regimen showed an impressive result in our previous study, but the effect of this new regimen is still dissatisfying for some patients, so it is necessary to identify which patients will benefit from this regimen. A total of fifty-one cases with nasal natural killer/T-cell lymphoma receiving initial GELOX chemotherapy were enrolled in this study. The ki-67 expression detected by immunohistochemistry (IHC) in the specimens ranged from 10% to 90%, with a median value of 70%, so cases higher than the median value (${\geq}70%$) were defined as high ki-67 expression, and the others were designated as low ki-67 expression. The response rate had no statistical difference between low ki-67 expression group and high ki-67 expression group (P=0.291) though the value in the former group was relatively high. After a median follow-up of 18.03 months, the 3-year progression-free survival (PFS) for patients with low ki-67 expression was significantly higher than those with high ki-67 expression (83.8% vs. 47.9%, P=0.038). In the stage I/II subgroup, 3-year PFS and overall survival (OS) were statistically higher in the patients with low ki-67 expression than those with high ki-67 expression. Multivariate analysis revealed high ki-67 expression was an independent prognostic factor for PFS. These results suggest that low ki-67 expression can predict a good response of GELOX in these patients, and the combination of ki-67 expression and early stage is helpful to identify an excellent prognosis subgroup from patients receiving GELOX in this disease.

#Ki-67 #gemcitabine #oxaliplatin #l-asparaginase #natural killer/T-cell lymphoma

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Zhang, Jing

소속기관 Department of Surgical Oncology, First Affiliated hospital, Zhejiang University, School of Medicine